Skip to Content
MDPIMDPI

Advanced

CancersCancers
PDF
  • Correction
  • Open Access

10 February 2020

5 Pages

Correction: Møller, P.; et al. Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift. Cancers 2019, 11, 132

,
,
and
1
Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Part of Oslo University Hospital, 0424 Oslo, Norway
2
Center for Hereditary Tumors, HELIOS-Klinikum Wuppertal, University ofWitten-Herdecke, 42283 Wuppertal, Germany
3
Department of Medical Genetics, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway
4
Center for Bioinformatics, Department of Informatics, University of Oslo, PO box 1080, Blindern, 0316 Oslo, Norway
Cancers2020, 12(2), 410;https://doi.org/10.3390/cancers12020410
This article belongs to the Special Issue BRCA Mutations and Cancer
Version Notes
Order Reprints
The authors wish to make the following corrections to this paper [1]:
The authors would like to replace Table 3 in [1]. The corrections are correcting typographical errors when translating our database in BIC format to HGVS nomenclature, and removing four carriers which had zero follow-up time. The original version of Table 3 is:
Table 3. Path_BRCA1 variants detected.
and should be replaced with the following Table 3:
Table 3. Path_BRCA1 variants detected.
The authors would like to apologize for any inconvenience caused to the readers by these changes.

Conflicts of Interest

The authors declare no conflict of interest.

Reference

  1. Møller, P.; Dominguez-Valentin, M.; Rødland, E.A.; Hovig, E. Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift. Cancers 2019, 11, 132. [Google Scholar] [CrossRef] [Scilit] [PubMed]

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells
Previous
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
Next